Literature DB >> 11152012

Diagnosis of pneumonia and monitoring of infection eradication.

M Ruiz1, C Arosio, P Salman, T T Bauer, A Torres.   

Abstract

Pneumonia can be classified as community-acquired (CAP) or hospital-acquired (nosocomial). Both are frequent infections that demand a great amount of medical resources. The diagnosis of CAP is based on clinical signs and the presence of a pulmonary infiltrate visible on chest radiograph. For practical purposes, CAP has been classified as typical, with an acute onset in which the most representative microorganism is Streptococccus pneumoniae, and atypical, with a subacute onset (Mycoplasma pneumoniae). Nevertheless, so far no studies have clearly demonstrated the utility of this classification in predicting the aetiology. Guidelines on CAP recommend associating the aetiology of CAP with comorbidity, age and severity. The microbiological diagnosis relies mainly on Gram stain and sputum culture, but this technique has disadvantages such as frequent contamination of the sample with oropharyngeal commensal flora, frequent sterile cultures associated with previous antibiotic treatment, and the fact that approximately 40% of patients are not able to expectorate. Other diagnostic techniques such as blood cultures, serological tests and fibreoptic bronchoscopy must be reserved for patients who are hospitalised, especially if they need admission to an intensive care unit. Compared with CAP, nosocomial pneumonia has major diagnostic problems due to the presence of other diseases able to mimic pneumonia and frequent bacterial colonisation of the lower respiratory tract. Most of the diagnostic techniques produce a high percentage of false-negative and false-positive results. This is especially true for ventilator-associated pneumonia. There is controversy over using a comprehensive aetiological work-up based on bronchoscopic techniques or only on quantitative culture of endotracheal aspiration. By contrast, there is consensus about the importance of the adequacy of empirical antibiotic treatment, since mortality rates are higher in patients who are inadequately treated. Once treatment of pneumonia has begun, it must be maintained for 48 to 72 hours because this is the minimum time to evaluate a clinical response. Antibacterial agents have to be adjusted according to microbiological findings. In nonresponding patients, pneumonia-related complications and the presence of multiresistant micro-organisms or non-covered pathogens must be ruled out.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152012     DOI: 10.2165/00003495-200060060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  64 in total

1.  Influence of age on symptoms at presentation in patients with community-acquired pneumonia.

Authors:  J P Metlay; R Schulz; Y H Li; D E Singer; T J Marrie; C M Coley; L J Hough; D S Obrosky; W N Kapoor; M J Fine
Journal:  Arch Intern Med       Date:  1997-07-14

Review 2.  Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

3.  Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome.

Authors:  M Ruiz; A Torres; S Ewig; M A Marcos; A Alcón; R Lledó; M A Asenjo; A Maldonaldo
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

4.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.

Authors:  M S Niederman; J B Bass; G D Campbell; A M Fein; R F Grossman; L A Mandell; T J Marrie; G A Sarosi; A Torres; V L Yu
Journal:  Am Rev Respir Dis       Date:  1993-11

5.  Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity.

Authors:  M Ruiz; S Ewig; M A Marcos; J A Martinez; F Arancibia; J Mensa; A Torres
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

6.  Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis.

Authors:  J T Macfarlane; A C Miller; W H Roderick Smith; A H Morris; D H Rose
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

7.  Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.

Authors:  J Y Fagon; J Chastre; A J Hance; P Montravers; A Novara; C Gibert
Journal:  Am J Med       Date:  1993-03       Impact factor: 4.965

Review 8.  The laboratory evaluation of opportunistic pulmonary infections.

Authors:  J H Shelhamer; V J Gill; T C Quinn; S W Crawford; J A Kovacs; H Masur; F P Ognibene
Journal:  Ann Intern Med       Date:  1996-03-15       Impact factor: 25.391

9.  C-reactive protein. A clinical marker in community-acquired pneumonia.

Authors:  R P Smith; B J Lipworth; I A Cree; E M Spiers; J H Winter
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

10.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  6 in total

Review 1.  Chest radiographs for acute lower respiratory tract infections.

Authors:  Amy Millicent Y Cao; Joleen P Choy; Lakshmi Narayana Mohanakrishnan; Roger F Bain; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2013-12-26

2.  Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.

Authors:  Yanhong Li; Joëlle Y Friedman; Betsy F O'Neal; Matthew J Hohenboken; Robert I Griffiths; Martin E Stryjewski; John P Middleton; Kevin A Schulman; Jula K Inrig; Vance G Fowler; Shelby D Reed
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

3.  Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial.

Authors:  Elizabeth Sapey; Jaimin M Patel; Hannah Greenwood; Georgia M Walton; Frances Grudzinska; Dhruv Parekh; Rahul Y Mahida; Rachel C A Dancer; Sebastian T Lugg; Philip A Howells; Jon Hazeldine; Paul Newby; Aaron Scott; Peter Nightingale; Adam T Hill; David R Thickett
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Detection of Viruses by Multiplex Real-Time Polymerase Chain Reaction in Bronchoalveolar Lavage Fluid of Patients with Nonresponding Community-Acquired Pneumonia.

Authors:  Hao Zhang; Yinling Han; Zhangchu Jin; Yinghua Ying; Fen Lan; Huaqiong Huang; Shaobin Wang; Hongwei Zhou; Rong Zhang; Wen Hua; Huahao Shen; Wen Li; Fugui Yan
Journal:  Can Respir J       Date:  2020-11-25       Impact factor: 2.409

5.  Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial.

Authors:  Chunxue Wang; Dongyang Zhao; Liang Zheng; Xiaowei Bao; Qian Yang; Sen Jiang; Xiaohui Zhou; Lunxian Tang; Zhongmin Liu
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

Review 6.  Acute bronchitis: state of the art diagnosis and therapy.

Authors:  Fernando J Martinez
Journal:  Compr Ther       Date:  2004
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.